S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$64.58
-1.4%
$64.77
$36.99
$70.81
$1.36B0.79138,754 shs184,179 shs
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$297.59
-0.7%
$300.42
$175.37
$329.87
$22.46B0.93468,272 shs592,268 shs
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
$2.78
-4.5%
$3.18
$2.01
$6.53
$386.36M1.522.06 million shs2.14 million shs
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
$1.51
+0.7%
$1.66
$1.50
$3.82
$25.35M0.8787,545 shs27,572 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-1.37%-5.18%-4.85%+16.55%+64.49%
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
-0.74%-8.18%-4.66%+15.89%+31.48%
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
-4.30%-7.95%-13.40%-24.66%-46.12%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
+0.33%+0.67%+0.67%-9.58%-35.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
4.709 of 5 stars
2.55.00.03.32.53.33.1
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
2.8759 of 5 stars
2.54.00.00.02.71.72.5
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
4.0613 of 5 stars
3.24.00.04.52.41.70.6
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
4.0697 of 5 stars
3.53.00.04.71.90.81.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$80.0023.88% Upside
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
2.90
Moderate Buy$312.645.06% Upside
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
2.40
Hold$4.2051.08% Upside
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
3.00
Buy$6.00297.35% Upside

Current Analyst Ratings

Latest UBX, ANIP, AXON, CYH, and EHE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
4/11/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $365.00
4/10/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$315.00 ➝ $400.00
3/15/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$80.00
3/13/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$380.00
3/6/2024
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$3.00
3/5/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $77.00
3/4/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$73.00 ➝ $83.00
3/1/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$72.00 ➝ $80.00
2/29/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$296.00 ➝ $308.00
2/28/2024
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $285.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$486.82M2.80$6.32 per share10.22$21.13 per share3.06
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$1.56B14.36$3.08 per share96.64$21.51 per share13.83
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
$12.49B0.03$2.26 per share1.23($8.38) per share-0.33
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
$240K105.64N/AN/A$4.71 per share0.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$18.78M$0.8476.8815.60N/A3.86%18.06%8.38%5/13/2024 (Estimated)
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$174.23M$2.30129.3991.01N/A11.14%14.11%6.61%5/14/2024 (Estimated)
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
-$133M-$1.03N/AN/AN/A-1.07%-5.51%-1.24%4/24/2024 (Confirmed)
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
-$59.93M-$2.94N/AN/AN/AN/A-88.92%-45.91%5/14/2024 (Estimated)

Latest UBX, ANIP, AXON, CYH, and EHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2024N/A
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
-$0.19N/A+$0.19N/AN/AN/A  
2/29/2024Q4 2023
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$0.58$0.78+$0.20$1.52$123.02 million$131.65 million
2/27/2024Q4 2023
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
$0.48$0.77+$0.29$0.79$418.97 million$432.14 million
2/21/2024Q4 2023
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
$0.03-$0.41-$0.44-$1.17$3.16 billion$3.18 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
N/AN/AN/AN/AN/A
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
N/AN/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
0.66
3.57
2.81
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
0.42
3.00
2.66
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
N/A
1.50
1.34
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/A
5.74
5.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
79.08%
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
84.99%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
12.70%
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
6.10%
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
9.90%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
64221.08 million18.40 millionOptionable
Axon Enterprise, Inc. stock logo
AXON
Axon Enterprise
4,26075.46 million70.86 millionOptionable
Community Health Systems, Inc. stock logo
CYH
Community Health Systems
61,000138.98 million125.22 millionOptionable
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
2216.79 million15.96 millionOptionable

UBX, ANIP, AXON, CYH, and EHE Headlines

SourceHeadline
Equities Analysts Issue Forecasts for Unity Biotechnology, Inc.s FY2024 Earnings (NASDAQ:UBX)Equities Analysts Issue Forecasts for Unity Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:UBX)
americanbankingnews.com - April 19 at 2:31 AM
Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)
americanbankingnews.com - April 18 at 1:26 AM
YOUTH UNITY EVENT TO BE HELD AT BOYS AND GIRLS CLUBYOUTH UNITY EVENT TO BE HELD AT BOYS AND GIRLS CLUB
kscj.com - April 17 at 7:01 PM
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC WainwrightUnity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC Wainwright
americanbankingnews.com - April 17 at 3:42 AM
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
investorplace.com - April 15 at 12:06 PM
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
globenewswire.com - April 15 at 7:00 AM
Unity Biotechnology, Inc. (0YC0.L)Unity Biotechnology, Inc. (0YC0.L)
finance.yahoo.com - April 9 at 7:15 PM
UBX Mar 2024 2.000 callUBX Mar 2024 2.000 call
finance.yahoo.com - February 17 at 6:28 AM
Unity Biotechnology Inc (UBX)Unity Biotechnology Inc (UBX)
uk.investing.com - February 7 at 9:59 AM
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision LossNew Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
finance.yahoo.com - February 6 at 10:46 AM
Guest column: UNITY is making strides in tackling homelessness in Tremes despite what critics sayGuest column: UNITY is making strides in tackling homelessness in Tremes despite what critics say
nola.com - February 1 at 6:40 PM
10 Supplements for Longevity and Antiaging: Expert Recommendations10 Supplements for Longevity and Antiaging: Expert Recommendations
finance.yahoo.com - December 29 at 6:53 PM
UNITY Biotechnology doses first patients in phase 2 ASPIRE study of UBX1325UNITY Biotechnology doses first patients in phase 2 ASPIRE study of UBX1325
pharmabiz.com - December 14 at 2:33 AM
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMEUNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
finance.yahoo.com - December 12 at 8:12 AM
Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63
msn.com - November 27 at 7:50 AM
Wedbush Upgrades Unity Biotechnology (UBX)Wedbush Upgrades Unity Biotechnology (UBX)
msn.com - November 17 at 6:09 AM
Wedbush upgrades Unity Biotechnology to outperform, cites cash runwayWedbush upgrades Unity Biotechnology to outperform, cites cash runway
msn.com - November 16 at 4:06 PM
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite RiskyCompanies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
finance.yahoo.com - November 16 at 11:05 AM
Unity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy RatingUnity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy Rating
markets.businessinsider.com - November 15 at 11:51 AM
Unity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUnity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
finanznachrichten.de - November 14 at 10:45 PM
Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16
msn.com - November 14 at 2:01 AM
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
tmcnet.com - November 13 at 9:00 PM
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
finance.yahoo.com - November 13 at 9:00 PM
UNITY Biotechnology to exercise warrants for $4.38M in gross proceedsUNITY Biotechnology to exercise warrants for $4.38M in gross proceeds
msn.com - November 10 at 2:17 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ANI Pharmaceuticals logo

ANI Pharmaceuticals

NASDAQ:ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Axon Enterprise logo

Axon Enterprise

NASDAQ:AXON
Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.
Community Health Systems logo

Community Health Systems

NYSE:CYH
Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. The company was incorporated in 1996 and is headquartered in Franklin, Tennessee.
Unity Biotechnology logo

Unity Biotechnology

NASDAQ:UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.